Tirzepatide — Research Overview

Also known as: Mounjaro, Zepbound

A dual GIP/GLP-1 receptor agonist FDA-approved under the brand names Mounjaro (diabetes) and Zepbound (weight management). The dual incretin mechanism produces greater weight loss than GLP-1 agonism alone, with clinical trials documenting average weight loss exceeding 20% of body weight in some populations.

Back to Peptide Encyclopedia